knowledge -WSS

knowledge

author：comprehensive 2025-09-05 11:27:33 - browse：35

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

WSS

Virginia high school admissions case could be legal follow

Covid vaccine financial winners and losers, from Pfizer to Novavax

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Patient advocates debate FDA's accelerated approval process

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Drug repurposing or repositioning? The language matters

Steward Health Care has deal to sell doctor network to UnitedHealth

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

As demand for Covid shots wanes, Moderna seeks its next success

Alkermes shareholders re

Medicare details structure of new drug price negotiation program

Alkermes shareholders re

Supreme Court strikes down use of affirmative action

In age of alternative facts, a scholarly course on calling out crap

Eliminate the waiting period for sterilization covered by Medicaid

knowledge

Eliminate the waiting period for sterilization covered by Medicaid

Apple is now the first public company to be valued at $3 trillion

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Hollywood unions extend contract negotiations for actors

In Memoriam: Notable people who died in 2023

Medical leaders decry Supreme Court decision on affirmative action

entertainment

knowledge

hotspot

Wikipedia